

FOI REF: 21/667

5th January 2022

Tel: 0300 131 4500
Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

Q1. How many patients were treated in November 2021 (or latest available month) by the dermatology department with the following drugs:

• Abrocitinib (Cibinqo)	0
• Baricitinib (Olumiant)	0
• Bimekizumab (Bimzelx)	0
• Brodalumab (Kyntheum)	0
• Dupilumab (Dupixent)	29
• Ixekizumab (Taltz)	0
• Risankizumab (Skyrizi)	0
• Guselkumab (Tremfya)	5
• Secukinumab (Cosentyx)	3
• Tildrakizumab (Ilumetri)	0
• Tralokinumab (Adtralza)	0
• Ustekinumab (Stelara)	33

Q2. How many patients were treated in November 2021 (or latest available month) by the rheumatology department with the following drugs:

• Baricitinib (Olumiant)	42
• Filgotinib (Jyseleca)	0
• Guselkumab (Tremfya)	0
• Ixekizumab (Taltz)	2
• Risankizumab (Skyrizi)	0
• Secukinumab (Cosentyx)	37
• Tofacitinib (Xeljanz)	11
• Upadacitinib (Rinvoq)	0
• Ustekinumab (Stelara)	3

Cont.../

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference.

Yours sincerely

Linda Thornhill (Mrs)
Corporate Governance Manager
esh-tr.foi@nhs.net